
Apellis Pharmaceuticals (APLS) shares soared on Tuesday after Biogen (BIIB) signed a definitive agreement to acquire the biopharmaceutical firm for about $5.6 billion in cash.
Biogen’s proposal values APLS shares at $41 each, representing a remarkable 140% premium over the price at which they closed on March 30.